1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Competitor Analysis: CD20 Antibodies 2015 - Biosimilars and Biosuperiors of Rituximab

Competitor Analysis: CD20 Antibodies 2015 - Biosimilars and Biosuperiors of Rituximab

This Competitive Intelligence Report about CD20 Antibodies 2015- Biosimilars and Biosuperiors of Rituximab provides a competitor evaluation in the field of recombinant antibodies targeting CD20 for treatment of B-cell mediated malignancies and rheumatoid arthritis as of March 2015. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The chimeric anti-CD20 antibody rituximab (Rituxan / MabThera) from Biogen Idec and Roche is one of the world’s commercially most successful antibodies (2014 sales of over US$ 6.9 bln). The commercial attractiveness of rituximab has stimulated companies to create and develop next generation anti-CD20 monoclonal antibodies with improved properties compared with the chimeric antibody rituximab. The forthcoming patent expiry for Rituxan / MabThera has boosted interest in and activties for developing biosimilar copies with the most advanced projects already approved and marketed in less regulated countries, but also in phase III studies in Western regulated markets.

The report includes a compilation of currently active projects in development of CD20 targeting antibodies for treatment of hematologic malignancies and rheumatoid arthritis and other autoimmune diseases. In addition, the report lists company-specific R&D pipelines of CD20 antibodies. Competitor projects are listed in a tabular format providing information on:

- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.


About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table Of Contents

Competitor Analysis: CD20 Antibodies 2015 - Biosimilars and Biosuperiors of Rituximab
Competitor Analysis: CD20 Antibodies 2015 - Biosimilars and Biosuperiors of Rituximab

Table of Contents
1. CD20 Antibodies 2015 - Biosimilars and Biosuperiors of Rituximab
2014 Sales of CD20 Antibodies
Marketed CD20 Antibodies and Sales
-           Rituxan/MabThera Pipeline and Sales
-           Gazyva/ Gazyvaro Pipeline and Sales
-           Arzerra Pipeline and Sales
-           Zevalin Pipeline and Sales
Biosuperior CD20 Antibodies
Biosimilar CD20 Antibodies
-           Rituxan/MabThera (rituximab) Biosimilars
2.  Corporate CD20 Antibody Biosimilar and Biosuperior Pipelines

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

  • $ 10995
  • Industry report
  • October 2016
  • by Global Data

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations Summary Hepatitis C is a blood-borne viral infection ...


Download Unlimited Documents from Trusted Public Sources

Biguanide Market

  • January 2017
    8 pages
  • Biguanide  

    Genetic  

    Chromosome  

View report >

Biological Therapy Industry in the US

  • January 2017
    9 pages
  • Vaccine  

  • United States  

View report >

Therapy Market in the UK

  • January 2017
    19 pages
  • Therapy  

  • United Kingdom  

View report >

Related Market Segments :

Therapy
Biosimilar
Targeted Therapy

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.